Answers are grounded in this paper and cite their sources.
The relationship between circulating Epstein–Barr virus (EBV) DNA and host-response variation within pediatric infectious mononucleosis (IM) remains incompletely characterized. We examined whether plasma viral load was associated with routine laboratory parameters and HIF-1α and Th17/Treg-related measures in an existing hospitalized cohort. This cross-sectional secondary analysis reused the 40 children with IM from a previously published case-control study; the 37 healthy controls were not reanalyzed. Plasma EBV-DNA was analyzed by Spearman correlation using log₁₀ copies/mL and categorically using a literature-derived threshold of 10⁴ copies/mL (low load, n = 17; high load, n = 23). The updated Table 4 contains 31 listed correlations. An exploratory source linear model assessed viral-load category and Th17 frequency with adjustment for age and body mass index. Bonferroni sensitivity analyses used the 61-test family described in Methods, subject to reconciliation of the test count. Median plasma EBV-DNA was 4.49 log₁₀ copies/mL (interquartile range, 3.65–4.88); no value was below the assay detection limit. In the updated Table 4, nominal positive correlations were reported for ALT ( r = 0.318), AST (0.348), ADA (0.406), CD3⁺ percentage (0.494), CD4⁺ percentage (0.657), CD3⁺/CD4⁺ ratio (0.682), Th17 frequency (0.323), Th17/Treg ratio (0.480), IL-17 A (0.555), HIF-1α (0.360), thrombin time (0.459), and lymphocyte count (0.387), and nominal negative correlations for CD4⁺/CD8⁺ ratio (− 0.620), Treg frequency (-0.458), TGF-β1 (-0.399), and platelet-to-lymphocyte ratio (− 0.501). None had a Bonferroni-adjusted P value below 0.05 when calculated from the displayed rounded P values using a 61-test correction. The updated analysis suggests exploratory relationships between plasma EBV-DNA and selected laboratory measures within a previously studied hospitalized pediatric IM cohort. It does not establish a consistent continuous association with HIF-1α or Th17-related measures. Small sample size, multiplicity, incomplete adjustment, and assay limitations preclude causal or clinical-use conclusions. Independent longitudinal validation is required.
No takes yet. Share an insight, caveat, or question.
Pang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: